Assessment of the Predictive Value of Anti-beta1AR and Anti-L-CaC Antibodies in the Evolution to Dilated Cardiomyopathy in Patients With Acute Viral Myocarditis

Launched by UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Dec 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of specific antibodies (anti-β1AR and anti-L-CaC) in predicting whether patients with acute viral myocarditis (a heart condition caused by a viral infection) will develop a more serious condition called dilated cardiomyopathy (DCM). About one-third of patients with acute viral myocarditis may face this progression, and understanding how these antibodies affect heart health could help doctors provide better care. The trial will involve around 300 patients aged 18 to 75 who have had symptoms for no more than 30 days.

Eligible participants will be those who have been diagnosed with viral myocarditis, and they will need to sign an informed consent form to join the study. Throughout the trial, participants can expect to have their blood tested to measure the levels of these antibodies, which will help researchers learn more about their potential role in heart function. This study aims to identify important markers that could guide treatment options for patients with viral myocarditis, ultimately improving outcomes for those at risk of developing DCM.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meets diagnostic criteria for VMC
• • 2. Clinical symptoms present for no more than 30 days
• • 3. Age ≥ 18 years and ≤ 75 years
• • 4. Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form.
• Exclusion Criteria:
• • 1. Serious uncontrolled infection at enrolment ("uncontrolled" is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment)
• • 2. Uncontrolled active bleeding at enrollment
• • 3. Systemic autoimmune disease such as systemic lupus erythematosus or diagnosed immunodeficiency disease at enrollment
• • 4. Pregnancy or breastfeeding
• • 5. Combination of serious diseases affecting survival, such as tumors, with a life expectancy shorter than 3 months
• • 6. Patients with poor compliance who are unable to complete the full course of the study
• • 7. Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.